Galapagos N.V. (GLPG) |
| 27.98 0.47 (1.71%) 06-04 11:58 |
| Open: | 27.5 |
| High: | 28.09 |
| Low: | 27.5 |
| Volume: | 2,385 |
| Market Cap: | 1,844(M) |
| PE Ratio: | 3.21 |
| Exchange: | NASDAQ |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 34.50 |
| Resistance 1: | 29.53 |
| Pivot price: | 28.63 |
| Support 1: | 27.92 |
| Support 2: | 26.92 |
| 52w High: | 37.78 |
| 52w Low: | 24.74 |
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Financials
| EPS | 8.710 |
| Book Value | 2.900 |
| PEG Ratio | 0.00 |
| Gross Profit | 8.551 |
| Profit Margin (%) | 46.83 |
| Operating Margin (%) | -982.92 |
| Return on Assets (ttm) | 10.7 |
| Return on Equity (ttm) | 16.3 |
Company news
Sat, 04 Jul 2026
GLPG Q1 2026 Earnings: Surprise Profit Beats Estimates Despite Revenue Void - Debt Analysis Report - dars.gov.et
Sat, 04 Jul 2026
GLPG Q1 2026 Earnings: Surprise Profit Beats Estimates Despite Revenue Void - Revenue Miss Report - dars.gov.et
Fri, 08 May 2026
LKFT Stock Price and Chart — EURONEXT:LKFT - TradingView
Wed, 06 May 2026
Galapagos (GLPG) posts Q1 2026 profit and commits up to €790M to Ouro deal - Stock Titan
Fri, 24 Apr 2026
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1 - Yahoo Finance
Sat, 04 Apr 2026
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
